Browse MAPK10

Summary
SymbolMAPK10
Namemitogen-activated protein kinase 10
Aliases JNK3; p493F12; p54bSAPK; PRKM10; JNK3A; SAPK1b; JNK3 alpha protein kinase; MAP kinase 10; MAP kinase p49 3F1 ......
Chromosomal Location4q22-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Membrane Lipid-anchor Nucleus Mitochondrion Note=Palmitoylation regulates MAPK10 trafficking to cytoskeleton. Recruited to the mitochondria in the presence of SARM1 (By similarity).
Domain PF00069 Protein kinase domain
Function

Serine/threonine-protein kinase involved in various processes such as neuronal proliferation, differentiation, migration and programmed cell death. Extracellular stimuli such as proinflammatory cytokines or physical stress stimulate the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway. In this cascade, two dual specificity kinases MAP2K4/MKK4 and MAP2K7/MKK7 phosphorylate and activate MAPK10/JNK3. In turn, MAPK10/JNK3 phosphorylates a number of transcription factors, primarily components of AP-1 such as JUN and ATF2 and thus regulates AP-1 transcriptional activity. Plays regulatory roles in the signaling pathways during neuronal apoptosis. Phosphorylates the neuronal microtubule regulator STMN2. Acts in the regulation of the amyloid-beta precursor protein/APP signaling during neuronal differentiation by phosphorylating APP. Participates also in neurite growth in spiral ganglion neurons. Phosphorylates the CLOCK-ARNTL/BMAL1 heterodimer and plays a role in the photic regulation of the circadian clock (PubMed:22441692).

> Gene Ontology
 
Biological Process GO:0000187 activation of MAPK activity
GO:0002764 immune response-regulating signaling pathway
GO:0002768 immune response-regulating cell surface receptor signaling pathway
GO:0007254 JNK cascade
GO:0007258 JUN phosphorylation
GO:0007623 circadian rhythm
GO:0009314 response to radiation
GO:0009416 response to light stimulus
GO:0031098 stress-activated protein kinase signaling cascade
GO:0032147 activation of protein kinase activity
GO:0033674 positive regulation of kinase activity
GO:0038093 Fc receptor signaling pathway
GO:0038095 Fc-epsilon receptor signaling pathway
GO:0042752 regulation of circadian rhythm
GO:0043405 regulation of MAP kinase activity
GO:0043406 positive regulation of MAP kinase activity
GO:0043410 positive regulation of MAPK cascade
GO:0045860 positive regulation of protein kinase activity
GO:0048511 rhythmic process
GO:0051090 regulation of sequence-specific DNA binding transcription factor activity
GO:0051403 stress-activated MAPK cascade
GO:0071900 regulation of protein serine/threonine kinase activity
GO:0071902 positive regulation of protein serine/threonine kinase activity
Molecular Function GO:0004674 protein serine/threonine kinase activity
GO:0004702 receptor signaling protein serine/threonine kinase activity
GO:0004705 JUN kinase activity
GO:0004707 MAP kinase activity
GO:0004708 MAP kinase kinase activity
GO:0004712 protein serine/threonine/tyrosine kinase activity
GO:0005057 receptor signaling protein activity
GO:0016909 SAP kinase activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04010 MAPK signaling pathway
hsa04012 ErbB signaling pathway
hsa04014 Ras signaling pathway
hsa04024 cAMP signaling pathway
hsa04068 FoxO signaling pathway
hsa04071 Sphingolipid signaling pathway
hsa04140 Regulation of autophagy
hsa04141 Protein processing in endoplasmic reticulum
hsa04210 Apoptosis
hsa04310 Wnt signaling pathway
hsa04380 Osteoclast differentiation
hsa04510 Focal adhesion
hsa04530 Tight junction
hsa04620 Toll-like receptor signaling pathway
hsa04621 NOD-like receptor signaling pathway
hsa04622 RIG-I-like receptor signaling pathway
hsa04664 Fc epsilon RI signaling pathway
hsa04668 TNF signaling pathway
hsa04722 Neurotrophin signaling pathway
hsa04723 Retrograde endocannabinoid signaling
hsa04728 Dopaminergic synapse
hsa04750 Inflammatory mediator regulation of TRP channels
hsa04910 Insulin signaling pathway
hsa04912 GnRH signaling pathway
hsa04914 Progesterone-mediated oocyte maturation
hsa04917 Prolactin signaling pathway
hsa04920 Adipocytokine signaling pathway
Reactome R-HSA-166054: Activated TLR4 signalling
R-HSA-450341: Activation of the AP-1 family of transcription factors
R-HSA-2559583: Cellular Senescence
R-HSA-2262752: Cellular responses to stress
R-HSA-2871796: FCERI mediated MAPK activation
R-HSA-2454202: Fc epsilon receptor (FCERI) signaling
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-450321: JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
R-HSA-450294: MAP kinase activation in TLR cascade
R-HSA-450282: MAPK targets/ Nuclear events mediated by MAP kinases
R-HSA-975871: MyD88 cascade initiated on plasma membrane
R-HSA-975155: MyD88 dependent cascade initiated on endosome
R-HSA-166166: MyD88-independent TLR3/TLR4 cascade
R-HSA-166058: MyD88
R-HSA-2559580: Oxidative Stress Induced Senescence
R-HSA-168180: TRAF6 Mediated Induction of proinflammatory cytokines
R-HSA-975138: TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
R-HSA-937061: TRIF-mediated TLR3/TLR4 signaling
R-HSA-168142: Toll Like Receptor 10 (TLR10) Cascade
R-HSA-181438: Toll Like Receptor 2 (TLR2) Cascade
R-HSA-168164: Toll Like Receptor 3 (TLR3) Cascade
R-HSA-166016: Toll Like Receptor 4 (TLR4) Cascade
R-HSA-168176: Toll Like Receptor 5 (TLR5) Cascade
R-HSA-168181: Toll Like Receptor 7/8 (TLR7/8) Cascade
R-HSA-168138: Toll Like Receptor 9 (TLR9) Cascade
R-HSA-168179: Toll Like Receptor TLR1
R-HSA-168188: Toll Like Receptor TLR6
R-HSA-168898: Toll-Like Receptors Cascades
Summary
SymbolMAPK10
Namemitogen-activated protein kinase 10
Aliases JNK3; p493F12; p54bSAPK; PRKM10; JNK3A; SAPK1b; JNK3 alpha protein kinase; MAP kinase 10; MAP kinase p49 3F1 ......
Chromosomal Location4q22-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MAPK10 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolMAPK10
Namemitogen-activated protein kinase 10
Aliases JNK3; p493F12; p54bSAPK; PRKM10; JNK3A; SAPK1b; JNK3 alpha protein kinase; MAP kinase 10; MAP kinase p49 3F1 ......
Chromosomal Location4q22-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MAPK10 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolMAPK10
Namemitogen-activated protein kinase 10
Aliases JNK3; p493F12; p54bSAPK; PRKM10; JNK3A; SAPK1b; JNK3 alpha protein kinase; MAP kinase 10; MAP kinase p49 3F1 ......
Chromosomal Location4q22-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MAPK10 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0960.783
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.6090.295
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.610.214
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.3280.454
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.3480.865
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.3120.894
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-1.0010.0469
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-1.5580.0476
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.5120.574
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3450.773
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.7110.659
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.290.143
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of MAPK10 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277302.7-2.71
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275903.4-3.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)2117195.913.10.355
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86250250.473
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.49.16.31
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91622.2022.20.12
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47500500.109
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolMAPK10
Namemitogen-activated protein kinase 10
Aliases JNK3; p493F12; p54bSAPK; PRKM10; JNK3A; SAPK1b; JNK3 alpha protein kinase; MAP kinase 10; MAP kinase p49 3F1 ......
Chromosomal Location4q22-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MAPK10. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMAPK10
Namemitogen-activated protein kinase 10
Aliases JNK3; p493F12; p54bSAPK; PRKM10; JNK3A; SAPK1b; JNK3 alpha protein kinase; MAP kinase 10; MAP kinase p49 3F1 ......
Chromosomal Location4q22-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MAPK10. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MAPK10.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMAPK10
Namemitogen-activated protein kinase 10
Aliases JNK3; p493F12; p54bSAPK; PRKM10; JNK3A; SAPK1b; JNK3 alpha protein kinase; MAP kinase 10; MAP kinase p49 3F1 ......
Chromosomal Location4q22-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MAPK10. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMAPK10
Namemitogen-activated protein kinase 10
Aliases JNK3; p493F12; p54bSAPK; PRKM10; JNK3A; SAPK1b; JNK3 alpha protein kinase; MAP kinase 10; MAP kinase p49 3F1 ......
Chromosomal Location4q22-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MAPK10 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMAPK10
Namemitogen-activated protein kinase 10
Aliases JNK3; p493F12; p54bSAPK; PRKM10; JNK3A; SAPK1b; JNK3 alpha protein kinase; MAP kinase 10; MAP kinase p49 3F1 ......
Chromosomal Location4q22-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MAPK10 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMAPK10
Namemitogen-activated protein kinase 10
Aliases JNK3; p493F12; p54bSAPK; PRKM10; JNK3A; SAPK1b; JNK3 alpha protein kinase; MAP kinase 10; MAP kinase p49 3F1 ......
Chromosomal Location4q22-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MAPK10 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting MAPK10.
ID Name Drug Type Targets #Targets
DB017822,6-Dihydroanthra/1,9-Cd/Pyrazol-6-OneSmall MoleculeMAPK10, MAPK8, MAPK8IP1, TTK4
DB02388Cyclohexyl-{4-[5-(3,4-Dichlorophenyl)-2-Piperidin-4-Yl-3-Propyl-3h-Imidazol-4-Yl]-Pyrimidin-2-Yl}AmineSmall MoleculeMAPK101
DB03084Cyclopropyl-{4-[5-(3,4-Dichlorophenyl)-2-[(1-Methyl)-Piperidin]-4-Yl-3-Propyl-3h-Imidazol-4-Yl]-Pyrimidin-2-Yl}AmineSmall MoleculeMAPK101
DB036239-(4-Hydroxyphenyl)-2,7-PhenanthrolineSmall MoleculeMAPK101
DB04395Phosphoaminophosphonic Acid-Adenylate EsterSmall MoleculeACTA1, CCT3, CFTR, CSNK2A1, DAPK1, DTYMK, EPHA2, EPHB2, GALK1, GSK ......26
DB06933N-(tert-butyl)-4-[5-(pyridin-2-ylamino)quinolin-3-yl]benzenesulfonamideSmall MoleculeMAPK101
DB07010N-BENZYL-4-[4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL]-1H-PYRROLE-2-CARBOXAMIDESmall MoleculeMAPK1, MAPK102
DB07217N-(3-cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)-2-fluorobenzamideSmall MoleculeMAPK101
DB080054-{[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino}-N-ethylpiperidine-1-carboxamideSmall MoleculeMAPK101
DB08010(3Z)-1-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-4-[(E)-2-phenylethenyl]-1H-indole-2,3-dione 3-oximeSmall MoleculeMAPK101
DB08011(3E)-5-fluoro-1-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-1H-indole-2,3-dione 3-oximeSmall MoleculeMAPK101
DB08015(3Z)-1-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-4-phenyl-1H-indole-2,3-dione 3-oximeSmall MoleculeMAPK101
DB080215-bromo-N-(3-chloro-2-(4-(prop-2-ynyl)piperazin-1-yl)phenyl)furan-2-carboxamideSmall MoleculeMAPK101
DB08023N-cyclohexyl-4-imidazo[1,2-a]pyridin-3-yl-N-methylpyrimidin-2-amineSmall MoleculeMAPK101
DB08025N-{2'-[(4-FLUOROPHENYL)AMINO]-4,4'-BIPYRIDIN-2-YL}-4-METHOXYCYCLOHEXANECARBOXAMIDESmall MoleculeMAPK101
DB080262-{4-[(4-imidazo[1,2-a]pyridin-3-ylpyrimidin-2-yl)amino]piperidin-1-yl}-N-methylacetamideSmall MoleculeMAPK101
DB085551-(3-bromophenyl)-7-chloro-6-methoxy-3,4-dihydroisoquinolineSmall MoleculeMAPK101